Nasdaq Biotechnology Ishares ETF IBB

$141.30 +1.07 (0.76%)

Valuation

Market cap
—
Revenue TTM
—
Net income TTM
—
P/E (trailing)
—
P/E (forward)
—
Profit margin
—
Debt to equity
—

Trading

Volume
552,023
Avg volume
—
Day's range
$140.40 – $141.78
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone
415-670-2000

Latest news

Stocktwits

BiotechSwings Nov 21, 9:25 AM
$XBI 140.18, $IBB 199.54 on Friday imo. both down over 2%, both under the 50 day, washed out into a week with real dates ngl
0 replies
thinkandpick Nov 21, 8:20 AM
$CCLD $XLV $IBB $XBI $VHT Healthcare stocks. Dirt-cheap and strongly profitable CareCloud (CCLD) will increase again its revenue and its profitability in 2027 compared to 2026 thanks to these developments alone: - The Empower acquisition that will contribute to the top and bottom lines for the ENTIRE 2027. - The multiple wins and new contracts from new and existing clients that were announced AFTER Q3 was out, because they will contribute to the top and bottom lines for the ENTIRE 2027. Facts here: https://www.globenewswire.com/news-release/2026/11/11/3400657/16541/en/carecloud-accelerates-wound-care-expansion-with-new-clients-ehr-integration-and-multimillion-dollar-payer-client-audit-wins.html and here : https://www.globenewswire.com/news-release/2026/11/18/3405619/16541/en/carecloud-accelerates-ai-powered-growth-with-over-40-reduction-in-claim-denials-and-multiple-new-rcm-wins.html
0 replies
BiotechSwings Nov 20, 7:55 PM
Afternoon check and nobody wants to own the sector into the weekend imo $XBI near 141.58, down 1.76% off a 144.12 close, and $IBB near 201.08, down 1.30% off 203.72 both are under their 50 day lines, XBI near 153.03 and IBB near 208.88, and both are down more than 5% in five sessions that is not a chase regime. it is washed out, weak hands out, watchlists getting built while the crowd argues doom single names with real dates still get my attention in a stretch like this. the sector can sit heavy and a name with a catalyst can still run on its own clock ngl
0 replies
MCRB_BULL Nov 20, 3:58 PM
$MCRB $XBI $IBB $XLV $12M MARKET CAP? ABSOLUTELY ABSURD! WE'RE TRADING AT LESS THAN HALF CASH ON HAND, WITH NO CONVENTIONAL DEBT. LET THAT SINK IN. WTF?! 🤯 The price action in the last few months makes it pretty obvious to me that this stock isn't trading organically. I believe there is deliberate price suppression and manipulation happening here to benefit someone in negotiations. No debt. Cash runway through at least March 2027. Compelling SER-155 data. Expanding irEC opportunity. Additional pipeline assets. Brutally oversold technicals. Extreme selling pressure, depressed sentiment, and a valuation that gives the pipeline less than ZERO CREDIT. And after the brutal selloff over the last several months, we STILL haven't seen a meaningful bounce. One of these days, this is going to produce a MASSIVE MOVE to the UPSIDE. I'm patiently waiting, continuing to accumulate, and holding onto the thesis that a major partnership or acquisition could be coming in the weeks ahead. 💰🚀
0 replies
BiotechSwings Nov 20, 2:27 PM
morning, and biotech is starting soft again imo $XBI closed Thursday at 144.12, down 0.63%, premarket near 143.5, down 0.43% still under the 50 day at 153.03, still holding just over the 200 day near 143.25 $IBB closed 203.72, down 0.81%, premarket near 203, under its 50 day at 208.88 $INSM is the premarket outlier, up about 20% early $SVRA is the other side, down about 16% premarket after FDA said it will not act by Nov 22, review still ongoing, no new date given
0 replies
robcarroll Nov 20, 2:02 PM
$SLS Think about who just bought and when. A J.P. Morgan and TD Cowen book placed 11.5M shares at $13 with institutional accounts. That is the level where funds were willing to write $150M of checks, after seeing the full REGAL topline, and the stock has traded above it every day since. Look at the timing. They put the money in before ASH on Dec 12 to 15, before the SLS009 newly diagnosed AML readout due this quarter, and before the J.P. Morgan Healthcare Conference in January. They positioned ahead of the catalysts, not after. Look at the terms. The 60 day lock-up on the company and insiders, plus the ATM being off limits until it expires, exists for one reason: to protect the buyers at $13 from new supply while those catalysts play out. Nobody negotiates that protection for a window they expect to be quiet. $275M in cash, zero new shares for 60 days, and the people who just committed $150M are sitting on a gain. That is the setup going into ASH. $XBI $IBB
3 replies
BiotechSwings Nov 20, 6:55 AM
Friday setup is not complicated imo $XBI closed Thursday at 144.12, down 0.63% after tagging 148.93 $IBB closed 203.72, down 0.81% both down more than 6% in five sessions and XBI still held that 143.59 low area that is washed out, not broken. watchlist work, not chase work ngl
0 replies
MCRB_BULL Nov 20, 12:49 AM
$MCRB $XBI $IBB $XLV Have you been paying attention to the broader market at all? This isn't an MCRB-specific collapse. We've just witnessed one of the worst selloffs in small and mid caps, particularly biotech. Hell even large caps lately. Look across XBI, IBB and the broader sector. This has been widespread, indiscriminate selling. Yes, the lack of a partnership announcement is frustrating, but attributing MCRB's entire decline to company-specific failure ignores the macro environment. Plenty of companies with legitimate pipelines, promising data and solid platforms have been crushed alongside it. I've been making this point repeatedly. You cannot evaluate MCRB in a vacuum. Look at the broader biotech market before concluding the market has written Seres off as a failure. Still here. Still accumulating. Still extremely bullish. I'm patiently waiting, continuing to accumulate, and holding onto the thesis that a major partnership or acquisition could be coming in the weeks ahead!
0 replies